A newly discovered molecule, OLE, has been found to restore the brain's immune cells to a more protective state in Alzheimer's disease models, according to a study published in Cell Death and Disease. The treatment reduced the accumulation of toxic plaques and improved memory performance, highlighting its potential as a promising new therapeutic strategy.
Research Overview
Researchers in Spain and Switzerland identified OLE, a molecule produced by the PM20D1 gene, which can reprogram microglia, the brain's immune cells, to regain their protective abilities. The study was led by Jose Vicente Sanchez Mut of the Institute for Neurosciences (IN), a joint center of the Spanish National Research Council (CSIC) and Miguel Hernandez University of Elche (UMH), together with Johannes Graff of the École Polytechnique Federale de Lausanne (EPFL).
How OLE Targets Alzheimer's Disease
One hallmark of Alzheimer's disease is the buildup of beta-amyloid plaques in the brain. Microglia, which normally help remove these toxic deposits, gradually become less effective and can contribute to neuronal damage. OLE helps microglia surround and contain beta-amyloid plaques, reducing both their size and harmful effects. In animal studies, the treatment also led to better performance on memory tests.
"One of the most significant findings is that we have identified a molecule capable of restoring microglia's protective function," explains Sanchez Mut. "In Alzheimer's disease, these cells become progressively impaired. Our results suggest that this process can be reversed, pointing to new therapeutic and research avenues to counteract the disease."
Testing OLE in Worms and Mice
To evaluate OLE, the researchers used several experimental models. First, they tested genetically modified worms (C. elegans) that produce beta-amyloid. Treatment with OLE reduced protein aggregates and improved movement, indicating a protective effect. Then, they tested the compound in mouse models of Alzheimer's disease. Mice received OLE for three months and showed better memory performance and fewer beta-amyloid plaques than untreated mice.
Microglia Show the Strongest Response
Single-cell analysis revealed that microglia were the cells most strongly affected by OLE. The treatment activated pathways involved in clearing beta-amyloid and helped microglia move toward plaques and contain them. "Single-cell analysis allowed us to determine that microglia were the cells that responded most strongly to the treatment," says Victoria Pozzi, first author of the study. Additional experiments in cell cultures showed that OLE improved microglial movement toward beta-amyloid deposits and directly protected neurons in culture.
Potential for Future Alzheimer's Therapies
The findings are covered by two European patents, including one owned by the CSIC. The researchers say this strengthens the translational potential of the work and supports future efforts to develop therapeutic applications based on the discovery.
